



THE FUTURE OF LIFE SCIENCES

*Reducing Costs While Ensuring
Quality & Value*

Prepared by

SCI_{SM}

Strategic Capital Investments LLC

636 Morris Turnpike, Suite 2H, Short Hills, New Jersey, 07078 USA

www.sci-llc-usa.com

Copyright 2008; All rights reserved worldwide by SCI LLC

Report Outline

This report entitled **“THE FUTURE OF LIFE SCIENCES – Reducing Costs While Ensuring Quality & Value”** provides key insights and examines the current status of the extremely vital life sciences industry. The emphasis of the report is on the foreseeable future for pharmaceuticals, biosciences and “drug discovery value chain”. We will cover the full picture including: research and development, design, discovery, and production. Globally, there is a demand for decreasing costs and increasing output of new quality drugs. This and other factors that will be discussed are creating a demand for end-to-end off shoring to countries in Asia such as India.

These needs and implications of end-to-end off shoring will be covered in-depth, as well as specific coverage of how the industry will be transformed in the next decade as policymakers, investors, and developers focus on the future life sciences with main aim of reducing cost of prescription drugs while ensuring quality.

Our aim is to provide accurate, relevant information and data, market trends, and highlights to investors, business executives, policymakers and other key stakeholders in the life sciences industry.

This report will begin with an overview (“big picture”) of the life sciences (biotech, pharmaceutical, etc) market and will then move into particular segments. Specific topics covered include: design, research and development, going-to-market, regulations, quality standards, and off shoring challenges. Our discussion of development will span from preclinical to late phases all the way up to commercial market penetration.

Several possible future scenarios occurring as a consequence of shift will be examined and the economic ramifications of each. The scope of discussion will span from the global perspective right down to the individual pharmaceutical consumer level. Ultimately, this report provides a roadmap to the process of re-engineering the life sciences industry with emphasis on enhancing value of assets under management (AUM) and increasing return on investment (ROI).

The report is organized into a crisp format with charts, tables, facts, and figures along with adequate reference materials.

For more details on the report; contact us at info@sci-llc-usa.com
